US Stem Cell Inc (OTCMKTS:USRM) is a micro-cap name that’s clearly begun to explode higher in recent days. The company has no clear headline catalyst and no other stem cell stocks are moving at all in recent days. It’s a bit of a mystery. However, we can see some clues if we take a closer look at the company’s recent headline flow and dig a bit under the surface.
In late January, the company’s Chief Scientific Officer, Kristin Comella, published her most recent publication. The piece was titled, “Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease”. The market reaction was clearly on display. However, the boards seem to suggest something about a lawsuit settlement with a standing issue with Northstar Biotech. It is possible there is something about to break more publicly about a resolution that has some bearing on the prospects for this company. We do not see much out there on it and don’t see any clear evidence of promotional activity.
US Stem Cell Inc (OTCMKTS:USRM) trumpets itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
U.S. Stem Cell’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
Find out when $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to company materials, “US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development, and commercialization of cell-based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.”
As noted by the company, the business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.
“Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities, as they do today for our general business operations. We believe the combination of our own therapeutics pipeline, combined with our revenue generating capabilities, provides the Company with a unique opportunity for growth and a pathway to profitability.”
Traders will note above 1000% during the past month in terms of shareholder gains in the name, a rally that has pushed up against longer standing distributive pressure in the stock. However, USRM has evidenced sudden upward volatility on many prior occasions. Furthermore, the stock has seen an influx in interest of late, with the stock’s recent average trading volume running exceeding 610% above its longer-run average levels.
At this time, carrying a capital value in the market of $2.1M, US Stem Cell has a store ($246K) of cash on the books, which compares with about $3.3M in total current liabilities. One should also note that debt has been growing over recent quarters. USRM is pulling in trailing 12-month revenues of $2.7M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 30.9%. We will update the story again soon as developments transpire. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!